Eosinophilic Organ Complications Associated with Dupilumab Therapy - Narrative Review and Current Evidence - PubMed
6 hours ago
- #Eosinophilic Complications
- #Pharmacovigilance
- #Dupilumab
- Dupilumab is effective for type 2 inflammatory diseases but can rarely cause eosinophilic adverse events.
- A literature review identified 52 cases, with symptoms like eosinophilic pneumonia, EGPA, and hypereosinophilic syndrome often appearing within three months of treatment.
- A case study highlighted a patient developing eosinophilic pleural effusions after nine months, resolving only after discontinuing dupilumab.
- VigiBase data shows significant reporting of eosinophilic events linked to dupilumab, including EGPA, HES, and eosinophilic pneumonia.
- Management typically involves stopping dupilumab and using corticosteroids, but rechallenge often leads to recurrence.
- Long-term monitoring and individualized risk assessments are recommended for patients on dupilumab therapy.